(-0.06%) 5 466.01 points
(0.08%) 39 143 points
(0.18%) 17 749 points
(0.05%) $80.87
(-5.04%) $2.62
(-0.79%) $2 312.30
(-0.08%) $28.85
(3.28%) $1 018.80
(0.34%) $0.936
(0.75%) $10.68
(0.49%) $0.792
(-0.27%) $87.25
-85.71% $ 0.000100
Live Chart Being Loaded With Signals
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient\'s CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient\'s tumor...
Stats | |
---|---|
Volumen de hoy | 30 268 |
Volumen promedio | 80 568 |
Capitalización de mercado | 0.00 |
EPS | $-0.230 ( Q1 | 2022-05-05 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (1 166.67%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-06-02 | Duvall Diantha | Sell | 1 355 | Common Stock |
2022-06-02 | Flechtner Jessica Baker | Sell | 1 578 | Common Stock |
2022-06-02 | Clark William D | Sell | 4 023 | Common Stock |
2022-06-01 | Sumer Jacquelyn L | Sell | 2 500 | Common Stock |
2022-05-31 | Clark William D | Sell | 117 244 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 92 transactions |
Buy: 40 896 126 | Sell: 84 760 217 |
Volumen Correlación
Genocea Biosciences, Inc. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Genocea Biosciences, Inc. Correlación - Moneda/Commodity
Genocea Biosciences, Inc. Finanzas
Annual | 2021 |
Ingresos: | $1.64M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.480 |
FY | 2021 |
Ingresos: | $1.64M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.480 |
FY | 2020 |
Ingresos: | $1.36M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.980 |
FY | 2019 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.890 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Genocea Biosciences, Inc.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient\'s CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient\'s tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico